Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer

Claudio Ceccarelli, Donatella Santini, Michela Gamberini, Mario Taffurelli, Pasquale Chieco, Simonetta Piana, Stefano Pileri, Domenico Marrano

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We tested three ErbB-2 monoclonal antibodies (MoAbs) specific to the intracytoplasmic internal domain (clone CB 11) and the extracellular glycosylated peptide domain (clones CBE1 and Tab250) in 351 primary invasive breast carcinomas. ErbB-2 immunodetection allowed us to differentiate three main groups: group 1 (62.7%) lacked both MoAb ErbB-2 domains (erb -/-); group 2 stained for both domains (erb +/+) (26.5%); group 3 stained for the internal domain only (erb +/-) (10.8%). The relationships among these groups and nodal status (N) were statistically significant, with N+ cases reaching the highest value (89.2%) in the erb +/- group. Lack of immunostaining in the external domain thus seems to be associated with increased metastatic spread. At variance analysis the difference in hormonal receptor content between groups 1 and 3 was not significant; while between groups 1 and 2 it was. The growth fraction of groups 2 and 3 was significantly higher than that of group 1. Our results showed that anti-ErbB-2 MoAb clone CB 11 was able to detect a higher number of ErbB-2 expressing cases than the two that are specific for the external domain (clones Tab 250 and CBE1). Due to the strong association between group 3 cases and the highest metastatic potential, this aggressive group could be identified only with the use of an internal-domain specific MoAb CB 11, which thus seems to present a better discriminative power as a diagnostic marker in the biopathological characterization of breast carcinoma.

Original languageEnglish
Pages (from-to)107-114
Number of pages8
JournalBreast Cancer Research and Treatment
Volume58
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Clone Cells
Breast Neoplasms
Analysis of Variance
Monoclonal Antibodies
Growth

Keywords

  • Breast carcinoma
  • Cancer metastasis
  • ErbB-2
  • Immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer. / Ceccarelli, Claudio; Santini, Donatella; Gamberini, Michela; Taffurelli, Mario; Chieco, Pasquale; Piana, Simonetta; Pileri, Stefano; Marrano, Domenico.

In: Breast Cancer Research and Treatment, Vol. 58, No. 2, 1999, p. 107-114.

Research output: Contribution to journalArticle

Ceccarelli, Claudio ; Santini, Donatella ; Gamberini, Michela ; Taffurelli, Mario ; Chieco, Pasquale ; Piana, Simonetta ; Pileri, Stefano ; Marrano, Domenico. / Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer. In: Breast Cancer Research and Treatment. 1999 ; Vol. 58, No. 2. pp. 107-114.
@article{613208641bd042119c97da3764ffdaa3,
title = "Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer",
abstract = "We tested three ErbB-2 monoclonal antibodies (MoAbs) specific to the intracytoplasmic internal domain (clone CB 11) and the extracellular glycosylated peptide domain (clones CBE1 and Tab250) in 351 primary invasive breast carcinomas. ErbB-2 immunodetection allowed us to differentiate three main groups: group 1 (62.7{\%}) lacked both MoAb ErbB-2 domains (erb -/-); group 2 stained for both domains (erb +/+) (26.5{\%}); group 3 stained for the internal domain only (erb +/-) (10.8{\%}). The relationships among these groups and nodal status (N) were statistically significant, with N+ cases reaching the highest value (89.2{\%}) in the erb +/- group. Lack of immunostaining in the external domain thus seems to be associated with increased metastatic spread. At variance analysis the difference in hormonal receptor content between groups 1 and 3 was not significant; while between groups 1 and 2 it was. The growth fraction of groups 2 and 3 was significantly higher than that of group 1. Our results showed that anti-ErbB-2 MoAb clone CB 11 was able to detect a higher number of ErbB-2 expressing cases than the two that are specific for the external domain (clones Tab 250 and CBE1). Due to the strong association between group 3 cases and the highest metastatic potential, this aggressive group could be identified only with the use of an internal-domain specific MoAb CB 11, which thus seems to present a better discriminative power as a diagnostic marker in the biopathological characterization of breast carcinoma.",
keywords = "Breast carcinoma, Cancer metastasis, ErbB-2, Immunohistochemistry",
author = "Claudio Ceccarelli and Donatella Santini and Michela Gamberini and Mario Taffurelli and Pasquale Chieco and Simonetta Piana and Stefano Pileri and Domenico Marrano",
year = "1999",
doi = "10.1023/A:1006357524171",
language = "English",
volume = "58",
pages = "107--114",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer

AU - Ceccarelli, Claudio

AU - Santini, Donatella

AU - Gamberini, Michela

AU - Taffurelli, Mario

AU - Chieco, Pasquale

AU - Piana, Simonetta

AU - Pileri, Stefano

AU - Marrano, Domenico

PY - 1999

Y1 - 1999

N2 - We tested three ErbB-2 monoclonal antibodies (MoAbs) specific to the intracytoplasmic internal domain (clone CB 11) and the extracellular glycosylated peptide domain (clones CBE1 and Tab250) in 351 primary invasive breast carcinomas. ErbB-2 immunodetection allowed us to differentiate three main groups: group 1 (62.7%) lacked both MoAb ErbB-2 domains (erb -/-); group 2 stained for both domains (erb +/+) (26.5%); group 3 stained for the internal domain only (erb +/-) (10.8%). The relationships among these groups and nodal status (N) were statistically significant, with N+ cases reaching the highest value (89.2%) in the erb +/- group. Lack of immunostaining in the external domain thus seems to be associated with increased metastatic spread. At variance analysis the difference in hormonal receptor content between groups 1 and 3 was not significant; while between groups 1 and 2 it was. The growth fraction of groups 2 and 3 was significantly higher than that of group 1. Our results showed that anti-ErbB-2 MoAb clone CB 11 was able to detect a higher number of ErbB-2 expressing cases than the two that are specific for the external domain (clones Tab 250 and CBE1). Due to the strong association between group 3 cases and the highest metastatic potential, this aggressive group could be identified only with the use of an internal-domain specific MoAb CB 11, which thus seems to present a better discriminative power as a diagnostic marker in the biopathological characterization of breast carcinoma.

AB - We tested three ErbB-2 monoclonal antibodies (MoAbs) specific to the intracytoplasmic internal domain (clone CB 11) and the extracellular glycosylated peptide domain (clones CBE1 and Tab250) in 351 primary invasive breast carcinomas. ErbB-2 immunodetection allowed us to differentiate three main groups: group 1 (62.7%) lacked both MoAb ErbB-2 domains (erb -/-); group 2 stained for both domains (erb +/+) (26.5%); group 3 stained for the internal domain only (erb +/-) (10.8%). The relationships among these groups and nodal status (N) were statistically significant, with N+ cases reaching the highest value (89.2%) in the erb +/- group. Lack of immunostaining in the external domain thus seems to be associated with increased metastatic spread. At variance analysis the difference in hormonal receptor content between groups 1 and 3 was not significant; while between groups 1 and 2 it was. The growth fraction of groups 2 and 3 was significantly higher than that of group 1. Our results showed that anti-ErbB-2 MoAb clone CB 11 was able to detect a higher number of ErbB-2 expressing cases than the two that are specific for the external domain (clones Tab 250 and CBE1). Due to the strong association between group 3 cases and the highest metastatic potential, this aggressive group could be identified only with the use of an internal-domain specific MoAb CB 11, which thus seems to present a better discriminative power as a diagnostic marker in the biopathological characterization of breast carcinoma.

KW - Breast carcinoma

KW - Cancer metastasis

KW - ErbB-2

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=0033451678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033451678&partnerID=8YFLogxK

U2 - 10.1023/A:1006357524171

DO - 10.1023/A:1006357524171

M3 - Article

C2 - 10674874

AN - SCOPUS:0033451678

VL - 58

SP - 107

EP - 114

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -